Total Asset Turnover
since 2005
Calculation
Celgene Corp., total asset turnover, long-term trends, calculation
| Total asset turnover | = | Net product sales1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|
| Dec 31, 2018 | 0.43 | = | 15,265) | ÷ | 35,480) |
| Dec 31, 2017 | 0.43 | = | 12,973) | ÷ | 30,141) |
| Dec 31, 2016 | 0.40 | = | 11,185) | ÷ | 28,086) |
| Dec 31, 2015 | 0.34 | = | 9,161) | ÷ | 27,053) |
| Dec 31, 2014 | 0.44 | = | 7,564) | ÷ | 17,340) |
| Dec 31, 2013 | 0.48 | = | 6,362) | ÷ | 13,378) |
| Dec 31, 2012 | 0.46 | = | 5,386) | ÷ | 11,734) |
| Dec 31, 2011 | 0.47 | = | 4,700) | ÷ | 10,006) |
| Dec 31, 2010 | 0.34 | = | 3,508) | ÷ | 10,177) |
| Dec 31, 2009 | 0.48 | = | 2,567) | ÷ | 5,389) |
| Dec 31, 2008 | 0.48 | = | 2,138) | ÷ | 4,445) |
| Dec 31, 2007 | 0.36 | = | 1,300) | ÷ | 3,611) |
| Dec 31, 2006 | 0.30 | = | 812) | ÷ | 2,736) |
| Dec 31, 2005 | 0.36 | = | 446) | ÷ | 1,247) |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
Net product sales exhibited a consistent and aggressive growth trajectory from 2005 through 2018, rising from 446 million to 15,265 million. Parallel to this, total assets expanded significantly, increasing from 1,247 million to 35,480 million. Despite the massive growth in both metrics, the total asset turnover ratio experienced periodic fluctuations, reflecting varying levels of efficiency in utilizing assets to generate revenue.
- Asset Utilization Peaks
- The total asset turnover ratio reached its highest levels of 0.48 in 2008, 2009, and 2013. These peaks indicate periods where revenue growth was most effectively aligned with the company's asset base.
- Impact of Rapid Asset Expansion
- Significant declines in the turnover ratio occurred in 2010 and 2015, both dropping to 0.34. These downturns coincide with substantial spikes in total assets; specifically, assets grew from 5,389 million in 2009 to 10,177 million in 2010, and from 17,340 million in 2014 to 27,053 million in 2015. The revenue growth during these specific years was insufficient to offset the rapid increase in the asset base, leading to a temporary reduction in efficiency.
- Recent Stabilization Trend
- Following the volatility observed in the first decade, the asset turnover ratio demonstrated a stabilizing trend between 2016 and 2018, settling at 0.43. This suggests a more consistent synchronization between the acquisition of assets and the realization of net product sales in the latter part of the analyzed period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Comparison to Competitors
Celgene Corp., total asset turnover, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2018 | 0.43 | 0.55 | 0.34 | 0.64 | 0.42 | 0.56 | 0.34 | 0.53 | 0.51 | 0.34 | 0.57 | 0.43 | 0.49 |
| Dec 31, 2017 | 0.43 | 0.40 | 0.27 | 0.62 | 0.39 | 0.51 | 0.37 | 0.49 | 0.46 | 0.31 | 0.67 | 0.37 | 0.70 |
| Dec 31, 2016 | 0.40 | 0.39 | 0.28 | 0.58 | 0.37 | 0.55 | 0.53 | 0.51 | 0.42 | 0.31 | 0.70 | 0.40 | 0.59 |
| Dec 31, 2015 | 0.34 | 0.43 | 0.29 | 0.52 | 0.43 | 0.56 | 0.62 | 0.53 | 0.39 | 0.29 | 0.73 | 0.41 | 0.41 |
| Dec 31, 2014 | 0.44 | 0.72 | 0.28 | 0.47 | 0.54 | 0.53 | 0.71 | 0.57 | 0.43 | 0.29 | 0.73 | 0.39 | 0.25 |
| Dec 31, 2013 | 0.48 | 0.64 | 0.28 | 0.42 | 0.55 | 0.66 | 0.48 | 0.54 | 0.42 | 0.30 | 0.71 | 0.41 | 0.52 |
| Dec 31, 2012 | 0.46 | 0.68 | 0.31 | 0.49 | 0.55 | 0.66 | 0.44 | 0.55 | 0.45 | 0.32 | 0.66 | 0.46 | 0.55 |
| Dec 31, 2011 | 0.47 | — | 0.31 | 0.64 | 0.54 | 0.72 | 0.47 | 0.57 | 0.46 | 0.36 | 0.34 | 0.44 | 0.64 |
| Dec 31, 2010 | 0.34 | — | 0.34 | 0.63 | 0.59 | 0.74 | 0.64 | 0.60 | 0.43 | 0.35 | 0.42 | 0.51 | 0.08 |
| Dec 31, 2009 | 0.48 | — | 0.36 | 0.61 | 0.57 | 0.80 | 0.67 | 0.65 | 0.24 | 0.23 | 0.51 | 0.47 | 0.05 |
| Dec 31, 2008 | 0.48 | — | 0.40 | 0.70 | 0.73 | 0.70 | 0.72 | 0.75 | 0.51 | 0.43 | 0.36 | 0.50 | 0.18 |
| Dec 31, 2007 | 0.36 | — | 0.41 | 0.74 | 0.63 | 0.70 | 0.64 | 0.75 | 0.50 | 0.42 | 0.13 | 0.46 | 0.33 |
| Dec 31, 2006 | 0.30 | — | 0.41 | 0.70 | 0.75 | 0.71 | 0.63 | 0.76 | 0.51 | 0.42 | 0.11 | 0.18 | 0.23 |
| Dec 31, 2005 | 0.36 | — | 0.41 | 0.68 | 0.87 | 0.60 | 0.48 | 0.87 | 0.49 | 0.44 | 0.16 | 0.62 | 0.29 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2018 | 0.43 | 0.45 |
| Dec 31, 2017 | 0.43 | 0.40 |
| Dec 31, 2016 | 0.40 | 0.41 |
| Dec 31, 2015 | 0.34 | 0.42 |
| Dec 31, 2014 | 0.44 | 0.44 |
| Dec 31, 2013 | 0.48 | 0.43 |
| Dec 31, 2012 | 0.46 | 0.45 |
| Dec 31, 2011 | 0.47 | 0.47 |
| Dec 31, 2010 | 0.34 | 0.47 |
| Dec 31, 2009 | 0.48 | 0.39 |
| Dec 31, 2008 | 0.48 | 0.57 |
| Dec 31, 2007 | 0.36 | 0.56 |
| Dec 31, 2006 | 0.30 | 0.54 |
| Dec 31, 2005 | 0.36 | 0.57 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., total asset turnover, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Dec 31, 2018 | 0.43 | 0.63 |
| Dec 31, 2017 | 0.43 | 0.56 |
| Dec 31, 2016 | 0.40 | 0.57 |
| Dec 31, 2015 | 0.34 | 0.55 |
| Dec 31, 2014 | 0.44 | 0.60 |
| Dec 31, 2013 | 0.48 | 0.58 |
| Dec 31, 2012 | 0.46 | 0.58 |
| Dec 31, 2011 | 0.47 | 0.61 |
| Dec 31, 2010 | 0.34 | 0.61 |
| Dec 31, 2009 | 0.48 | 0.55 |
| Dec 31, 2008 | 0.48 | 0.73 |
| Dec 31, 2007 | 0.36 | 0.71 |
| Dec 31, 2006 | 0.30 | 0.69 |
| Dec 31, 2005 | 0.36 | 0.66 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).